[Efficacy of different doses of magnesium isoglycyrrhizinate in the treatment of chronic liver disease with elevated ALT: a meta-analysis].

To investigate the efficacy and safety profile of different doses of magnesium isoglycyrrhizinate in the treatment of chronic liver disease with elevated alanine aminotransferase (ALT). Computer retrieval of literature was conducted in the CNKI, Wanfang, and PubMed databases from the establishment of the databases until February 2023. The Cochrane risk of bias assessment tool was used to evaluate the quality of the included literature after screening the literature and extracting the data. RevMan 5.4 and Stata 15.0 software were used to analyze the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), total effective rate, and incidence of adverse events. Finally, 10 articles were selected, including a total of 1 522 cases. All the included studies were of good quality and at low risk of bias. Meta-analysis results showed that compared with 100 mg/d magnesium isoglycyrrhizinate injection, 200 mg/d magnesium isoglycyrrhizinate injection had significantly reduced patients' ALT [ = -30.73, 95% confidence interval (): -52.52 ~ -8.94, = 2.76, = 0.006; (2) = 98%, < 0.001], AST ( = -34.30, 95% : -57.78 ~ -10.82, = 2.86, = 0.004; (2) = 99%, < 0.001) and TBil ( = -15.37, 95% : -27.66 ~ -3.09), = 2.45, = 0.01; (2) = 98%, < 0.001) levels. The total effective rate reported in seven articles showed no heterogeneity among the studies ( (2) = 0.0%, = 0.98). The total effective rate was higher in 200 mg/d magnesium isoglycyrrhizinate injection than that of 100 mg/d magnesium isoglycyrrhizinate injection ( = 3.49, 95% : 2.05 ~ 5.95, = 4.59, < 0.001), and there was no statistically significant difference in adverse reactions. 200 mg/d magnesium isoglycyrrhizinate injection can more rapidly and effectively improve the levels of ALT, AST, and TBil in patients with chronic liver disease, with an increased total effective rate and a good safety profile.